Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system - Poll - MDSpire

Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system

  • By

  • Keyuan Du

  • Chenglong Duan

  • Jiaqi Zhang

  • Jianing Zhang

  • Jinsui Du

  • Yi Pan

  • Zhihao Liu

  • Chenrong Zhang

  • Yuhan Zhang

  • Yibin Zhang

  • Xuan Zhang

  • Zhongxia Sheng

  • Bin Wang

  • Yu Ren

  • Lizhe Zhu

  • June 10, 2026

  • 0 min

Share

Original Source(s)

Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system

  • by Keyuan Du, Chenglong Duan, Jiaqi Zhang, Jianing Zhang, Jinsui Du, Yi Pan, Zhihao Liu, Chenrong Zhang, Yuhan Zhang, Yibin Zhang, Xuan Zhang, Zhongxia Sheng, Bin Wang, Yu Ren, Lizhe Zhu

  • June 10, 2026

Related Content

Tertiary lymphoid structures in breast cancer: formation, immune functions and clinical implications

Predicting preoperative axillary lymph node metastasis to guide surgical decisions in invasive breast cancer

Plasma cytokine profiles in breast cancer patients and their association with therapeutic response in Peru: a prospective cohort study